GALNT6 and ovarian cancer: Furthermore, an EGFR inhibitor, erlotinib, reversed the effects of GALNT6 overexpression on malignant behavior of ovarian cancer cells, indicating that EGFR is a key mediator of GALNT6 effects on ovarian cancer cells.